Argus Research Maintains Buy on Novo Nordisk, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
Argus Research has maintained its Buy rating on Novo Nordisk (NYSE:NVO) and raised the price target from $125 to $160.
June 10, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has maintained its Buy rating on Novo Nordisk and raised the price target from $125 to $160.
The raised price target and maintained Buy rating from Argus Research are positive signals for investors, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100